Pioneering European research project
We are proud to announce our participation in the EU-funded project Elucidating Pathways of Steatohepatitis (EPoS) aimed at developing better diagnostic tests and treatments for patients with non-alcoholic fatty liver disease. Our role is to validate our biomarkers as diagnostic and prognostic markers to identify the most severely affected patients who might progress to liver cirrhosis or cancer. This will be the largest study of its kind to connect research from across the continent in liver disease, enabling a greater insight into factors linked to the development NAFLD.
FDA application submitted for C1M ELISA
In pursuance of our dedication to provide the highest quality of biomarkers, we submitted our application for regulatory approval of our C1M ELISA to the US FDA on May 11, 2015.
The American Society of Clinical Oncology’s World Conference
The American Society of Clinical Oncology’s (ASCO) World Conference on cancer will take place in Chicago May 29 - June 2, 2015. Nordic Bioscience will present the use of our Protein Fingerprint biomarkers for prediction of cancer related mortality and early diagnosis in "The Prospective Epidemiologic Risk factor”- study (PERF I) that includes 5,856 patients followed for up to 15 years.